Comparative Pharmacology
Head-to-head clinical analysis: CEREZYME versus NEXVIAZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEREZYME versus NEXVIAZYME.
CEREZYME vs NEXVIAZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imiglucerase is a recombinant form of the lysosomal enzyme β-glucocerebrosidase, which catalyzes the hydrolysis of glucocerebroside to glucose and ceramide. It replaces deficient endogenous enzyme in patients with Gaucher disease, reducing accumulated glucocerebroside in macrophages.
Avalglucosidase alfa is a recombinant human acid alpha-glucosidase (GAA) that replaces deficient GAA, cleaving lysosomal glycogen and reducing accumulation.
60 units/kg intravenously every 2 weeks; infusion rate not to exceed 1 mg/min (equivalent to 2 units/kg/min).
Intravenous infusion of 20 mg/kg of actual body weight once every 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 3.6–10.4 hours (median 5.8 hours) after IV infusion. Clinical context: supports weekly or biweekly dosing (30–60 IU/kg every 2 weeks).
30.7 hours (range 23.8-38.7) in patients with infantile-onset Pompe disease; supports every 2-week dosing.
Primarily metabolized via proteolysis into small peptides and amino acids; renal excretion of metabolites is minimal (<5% unchanged). Biliary/fecal excretion not quantified due to protein nature.
Primarily cleared via receptor-mediated endocytosis followed by lysosomal degradation; minimal renal excretion (<3% unchanged in urine).
Category C
Category C
Enzyme replacement therapy
Enzyme replacement therapy